Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful

Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin’s lymphoma

(2010) Anastasios Chatzitolios et al.   ANNALS OF HEMATOLOGY

Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study

(2010) Zi Chen et al.   MEDICAL ONCOLOGY

Diffuse Aggressive B-cell Lymphomas

(2009) Jonathan Said   ADVANCES IN ANATOMIC PATHOLOGY

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas

(2009) Heidi Nyman et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma

(2009) Laurence de Leval et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

(2009) Heidi Nyman et al.   MODERN PATHOLOGY

Diffuse Large B-Cell Lymphoma

(2008) Jonathan W. Friedberg et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas

(2008) Kisha A. Mitchell et al.   LEUKEMIA & LYMPHOMA

Distinct Gene Expression Profiles: Nodal versus Extranodal Diffuse Large B-Cell Lymphoma

(2008) Zeenath Jehan et al.   ONCOLOGY

Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia

(2008) Suat-Cheng Peh et al.   PATHOLOGY INTERNATIONAL